Cancer News
OncoLink Cancer News - HealthDay


New Drug Approved for Chemo-Related Severe Neutropenia

Friday, August 31, 2012 (Last Updated: 09/04/2012)

FRIDAY, Aug. 31 (HealthDay News) -- The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have severe neutropenia, the FDA said in a news release.

Tbo-filgrastim stimulates the bone marrow to increase output of neutrophils. The new drug, injected about 24 hours after chemotherapy is administered, is meant for adults who do not have cancers of the blood or bone marrow, the FDA said.

Tbo-filgrastim was evaluated among 348 adults with advanced breast cancer who received the chemotherapy drugs doxorubicin and docetaxel. People who received the tbo-filgrastim recovered from severe neutropenia in an average of 1.1 days, compared with 3.8 days among adults given a placebo, the agency said.

Bone pain was the most common side effect of the new drug observed in clinical testing, the FDA said.

Tbo-filgrastim is produced by Sicor Biotech, a unit of the Israeli pharmaceutical firm Teva Corp.

Specialties Hematology & Oncology
Pharmacy

Copyright © 2012 HealthDay. All rights reserved.


I Wish You Knew

Getting through cancer treatment: tips from an oncology nurse

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More